论文部分内容阅读
目的:观察CHG预激方案对老年AML疗效及血清VEGF表达的影响。方法:2004-06/2008-06我科确诊的AML患者48例,随机分为CHG预激组和CAG标准预激对照组。对比其疗效和不良反应发生率,同时ELASA法测定患者治疗前后血清中VEGF变化。结果:CHG组在疗效、血液学毒性发生率、血中VEGF下降水平与CAG组差异有统计学意义,但在非血液学毒性两组差异无统计学意义。结论:CHG方案用于AML可获得较好的效果,血中VEGF监测可作为预后的监测指标。
Objective: To observe the effect of CHG pre-excitation program on the therapeutic effect of aged AML and serum VEGF expression. METHODS: Forty-eight AML patients diagnosed in our department from June 2004 to June 2008 were randomly divided into CHG pre-excitation group and CAG standard pre-excitation control group. The curative effect and incidence of adverse reactions were compared. At the same time, ELASA method was used to determine the change of serum VEGF in patients before and after treatment. Results: The curative effect, the incidence of hematological toxicity and the level of VEGF in blood of CHG group were significantly different from that of CAG group, but there was no significant difference in non-hematologic toxicity between two groups. Conclusion: CHG regimen can be used in AML to get good results. Blood VEGF monitoring can be used as a prognostic indicator.